These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38977180)

  • 1. Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism.
    Lakdawalla DN; Phelps CE; Nguyen HH
    Value Health; 2024 Jul; ():. PubMed ID: 38977180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
    Dabbous O; Chachoua L; Aballéa S; Sivignon M; Persson U; Petrou S; Richardson J; Simoens S; Toumi M
    Adv Ther; 2023 Feb; 40(2):393-424. PubMed ID: 36451072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of mortality risk reductions. Pure altruism - a confounder?
    Gyrd-Hansen D; Kjær T; Seested Nielsen J
    J Health Econ; 2016 Sep; 49():184-92. PubMed ID: 27494571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method.
    Tan S; Wang Y; Tang Y; Jiang R; Chen M; Chen H; Yang F
    Front Public Health; 2022; 10():1005453. PubMed ID: 36579068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure altruism and misjudgement: A bad combination?
    Simonsen NF; Kjær T; Gyrd-Hansen D
    J Health Econ; 2021 Dec; 80():102550. PubMed ID: 34794008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the (Near) Equivalence of Welfarist and Extra-Welfarist Methods to Value Healthcare With Implications for Assessing Equity.
    Phelps CE
    Value Health; 2023 Nov; 26(11):1601-1607. PubMed ID: 37597613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altruistic preferences for life-saving public programs: do baseline risks matter?
    Van Houtven GL
    Risk Anal; 1997 Feb; 17(1):85-92. PubMed ID: 9131828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impacts of altruism levels on the job preferences of medical students: a cross-sectional study in China.
    Zhang Y; Lin X; Li X; Han Y
    BMC Med Educ; 2023 Jul; 23(1):538. PubMed ID: 37501080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
    Bourke SM; Plumpton CO; Hughes DA
    Value Health; 2018 May; 21(5):538-546. PubMed ID: 29753350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of utility functions and psychological altruism.
    Clavien C; Chapuisat M
    Stud Hist Philos Biol Biomed Sci; 2016 Apr; 56():24-31. PubMed ID: 26598465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination and altruism under the COVID-19 pandemic.
    Cato S; Iida T; Ishida K; Ito A; Katsumata H; McElwain KM; Shoji M
    Public Health Pract (Oxf); 2022 Jun; 3():100225. PubMed ID: 35036971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
    Park T; Griggs SK; Suh DC
    BioDrugs; 2015 Aug; 29(4):259-74. PubMed ID: 26263903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational and Neurobiological Substrates of Cost-Benefit Integration in Altruistic Helping Decision.
    Hu J; Hu Y; Li Y; Zhou X
    J Neurosci; 2021 Apr; 41(15):3545-3561. PubMed ID: 33674417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The allocation of organs donated by altruistic strangers.
    Steinberg D
    Ann Intern Med; 2006 Aug; 145(3):197-203. PubMed ID: 16880461
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.